|
Patent landscape, scope, and claims: |
United States Patent 7,572,920 Landscape: Process, Composition, and Combination Claims for an Angiotensin II Antagonist
Executive summary: U.S. Patent 7,572,920 is a core US patent family component with broad claim coverage across (1) chemical process steps to make an angiotensin II antagonist API, (2) drug product composition (API + pharmaceutically acceptable carrier), and (3) therapeutic and combination method-of-use claims for hypertension mediated by angiotensin II, including fixed combinations with calcium antagonists, diuretics, insulin sensitizers, and biguanides. The claim set is structured to support both commercial product protection (composition) and regulatory/litigation leverage via method and combination claims that can be implicated by generic labeling (and by branded combination product launch strategy).
What does US Patent 7,572,920 claim cover? (Scope of claims 1–18)
Featured snippet answer: The patent claims cover a specific benzimidazole-oxadiazole angiotensin II antagonist defined by a carboxylate ester scaffold, a manufacturing process for producing that compound, and pharmaceutical compositions plus methods for treating angiotensin II-mediated hypertension, including combination therapy with multiple drug classes.
Claim 1: Chemical process scope
Claim 1 is a process claim directed to producing the compound where R2 is methyl or a salt. It requires reacting a reactive derivative of a benzimidazole-7-oxylic acid precursor with a compound represented by a second formula (also where R2 is methyl or salt).
Scope implications:
- The claim is not a general “make any salt” claim; it is anchored to the specific precursor identity (reactive derivative of the named benzimidazole-7-oxylic acid system containing the 2-ethoxy group and the biphenyl-oxadiazole substituent).
- The key enforceability hinge is whether accused manufacture uses the claimed reactive derivative and the claimed coupling with the R2-defined partner.
Claims 2–4: Composition + therapeutic indication
- Claim 2: pharmaceutical composition comprising the API:
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate, or salt + carrier.
- Claim 3: composition of claim 2 “is an angiotensin II antagonist.”
- Claim 4: composition of claim 2 “is an agent for treatment of hypertension.”
Scope implications:
- Claim 2 is a product-by-composition claim. It is strongest against products that use the same API (or its salts) with acceptable carriers.
- Claims 3–4 add functional/therapeutic language but they are tied to the defined API in claim 2, which can matter for claim construction in practice.
Claims 5–6: Combination with calcium antagonist
- Claim 5: composition comprising the API + calcium antagonist.
- Claim 6: claim 5 for hypertension treatment.
Scope implications:
- This is an enforceability lever against fixed combination products or label-advised combination regimens if the generic enters with a combination product structure that matches the claim.
Claims 7–8: Method for antagonizing angiotensin II / treating hypertension
- Claim 7: method for antagonizing angiotensin II by administering an effective amount of the API (or salt) to a mammal.
- Claim 8: method for treating angII-mediated hypertension.
Scope implications:
- These claims are method-of-use. They are typically implicated by labeling/indication rather than by manufacturing steps, depending on the jurisdiction and infringement theory.
- “Mammal” is broad (human included) and not limited by route, dosing schedule, or age.
Claims 9–11: Combination with calcium antagonist / diuretic agent
- Claim 9: same as claim 8 plus combination with calcium antagonist.
- Claim 10: composition with diuretic agent.
- Claim 11: method with diuretic agent.
Scope implications:
- Creates multiple infringement pathways for combination therapy: composition and method claims both exist.
Claims 13–18: Combination with insulin sensitizer / biguanide
- Claim 13–14: composition + insulin sensitizer, plus hypertension treatment.
- Claim 15–16: composition + biguanide.
- Claim 17–18: methods for treating angII-mediated hypertension in combination with insulin sensitizer or biguanide.
Scope implications:
- The patent anticipates therapeutic adjacency in patients with metabolic comorbidities (diabetes-related insulin resistance) by covering combinations with insulin sensitizers and biguanides.
- “Biguanide” is a meaningful class definition; it captures metformin-type regimens to the extent a claimed combination product or regimen matches the claim language.
How broad is the compound definition in US 7,572,920? (R2 methyl vs salt; ester scaffold)
Key definitional anchors
- Core scaffold: benzimidazole substituted with:
- 2-ethoxy group
- biphenyl motif linked to 1,2,4-oxadiazol-3-yl (with a 5-oxo, 4,5-dihydro pattern)
- carboxylate ester: “(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl … benzimidazole-7-carboxylate”
- R2 limitation: methyl or a salt thereof.
Practical claim breadth takeaways
- The compound identity is highly specific, which narrows literal infringement to the defined chemical entity and its covered salt form(s).
- The explicit “salt” language increases coverage for formulation strategies using pharmaceutically acceptable salts, but the claim still requires the same chemical entity skeleton.
Which parts of US 7,572,920 are hardest to design around? (Process vs composition vs method claims)
Design-around risk ranking (typical enforcement economics)
- Claim 2 composition (API + carrier)
- If a generic sells the same API, design-around is difficult without changing the active ingredient or salt form.
- Claims 5, 10, 13, 15 combination compositions
- Harder when the generic pursues fixed-dose combinations that track the claim’s partner class.
- Claims 7–9, 11, 17–18 method claims
- These can be harder to neutralize if labeling stays within the claimed method statements for angiotensin II antagonism and angII-mediated hypertension, especially in combination indications.
- Claim 1 process claim
- Process design-around is possible if a competitor uses a materially different synthetic route that avoids the specific reactive precursor/coupling scheme. However, proving non-infringement can be evidentiary-heavy.
What patents protect the same drug scaffold? (How 7,572,920 fits in a typical IP stack)
Executive summary: Based on claim architecture, the patent looks like a compound-centric + formulation/combination layer. In a US-centric litigation posture, the likely landscape is an IP stack that includes:
- a primary compound patent (claims directly to the active entity),
- one or more salt/form patents (if salt forms were pursued),
- process patents like claim 1,
- formulation patents (dosage forms and excipients),
- method-of-use and combination patents (as seen here).
This patent itself is unusually “bushy” across process + composition + methods + multi-class combinations, which often indicates it functions as a near-core “bridge” around the compound’s entry window.
When does exclusivity or patent protection end for claims like these? (Litigation-relevant timing structure)
Featured snippet answer: The practical freedom-to-operate timeline is driven by (1) the patent term for US 7,572,920, (2) any patent term adjustment (PTA), and (3) any regulatory exclusivity tied to the first FDA approval.
Because the prompt provides only the claim text and not the filing/priority/expiration or FDA approval identifiers, no definitive expiration date can be computed here.
What generic entry risks exist for a product matching claim 2? (Paragraph IV and label-driven exposure)
Risk pathways
- Literal infringement risk: a generic that sells the same API (or same salt form) in a pharmaceutically acceptable carrier aligns with claim 2.
- Method and combination risk: generics frequently seek label indications that track or mirror branded claims. If the generic label includes:
- angII antagonism language, or
- “hypertension mediated by angiotensin II,” or
- fixed-dose combinations / combination regimens with the claimed partner classes,
then method/composition combination claims can be implicated.
Paragraph IV posture
- If US 7,572,920 is listed in the FDA Orange Book for the relevant NDA/ANDA, a Paragraph IV certification can trigger litigation under the Hatch-Waxman framework.
- Even absent fixed-dose combinations, label-driven method claims can generate enforcement leverage because they map to prescribing instructions.
Which combination partners are covered by US 7,572,920 and what does that mean commercially?
Covered partner classes (from claim set)
- Calcium antagonists (claims 5, 6, 9)
- Diuretic agents (claims 10, 11)
- Insulin sensitizers (claims 13, 14, 17)
- Biguanides (claims 15, 16, 18)
Commercial implication
- The patent anticipates combination therapy across distinct competitor generic entry strategies:
- hypertension fixed-dose combinations (calcium antagonist + ARB/ACE-like comparators),
- diuretic add-ons,
- metabolic comorbidity combinations in patients likely to have insulin resistance.
How does US 7,572,920 compare with typical hypertension antagment patent estates?
Featured snippet answer: This patent has both product and method-of-use claims, plus multiple combination claims, which is more comprehensive than many estates that split compound claims from later “use” patents.
What the claim mix suggests
- It targets the core API with composition claims.
- It provides multiple infringement anchors even if a generic tries to avoid a composition claim via labeling differences, because method claims can still be asserted.
- It supports combination licensing or settlement leverage by offering several “named” partner classes rather than one combination.
What Orange Book status would matter most for US 7,572,920? (Listings and certifications)
Featured snippet answer: Orange Book listing of US 7,572,920 against the relevant NDA/ANDA is the central commercial trigger for generic certification and potential Paragraph IV litigation exposure.
Because the prompt does not provide the drug’s trade name, NDA/ANDA number, or Orange Book listing details, no specific Orange Book entry can be asserted here.
What patent litigation issues are likely raised by claim 1 vs claims 2–18?
Typical litigation focus
- Claim 1 process
- Disputes over whether the accused synthesis uses the “reactive derivative” of the specific benzimidazole-7-oxylic acid intermediate and the required coupling partner.
- Claim 2 composition
- Whether the accused product contains the same API (or a covered salt form) and uses a “pharmaceutically acceptable carrier.”
- Combination claims (5, 9, 10, 11, 13, 14, 15, 16, 17, 18)
- Whether the accused product is a fixed combination and whether the co-ingredient qualifies as the claimed class.
- Method claims (7–9, 11, 17–18)
- Whether the label indication, instructions, or usage practice maps to the claimed “angII antagonism” and “angII-mediated hypertension” treatment statements.
Key Takeaways
- US 7,572,920 covers manufacture, drug product composition, and method-of-use for a specific benzimidazole-oxadiazole angiotensin II antagonist defined down to the carboxylate ester and R2 = methyl or salt.
- The enforcement architecture is reinforced by multiple combination claims with calcium antagonists, diuretics, insulin sensitizers, and biguanides.
- From a freedom-to-operate standpoint, the most difficult-to-design-around elements are claim 2 (same API) and the combination composition claims if a generic targets fixed-dose combinations aligned to those classes.
- The process claim (claim 1) creates an additional pathway for infringement allegations against manufacturing routes, but it is typically more design-around-friendly if the competitor can shift synthetic strategy away from the claimed reactive derivative coupling.
FAQs
- What elements control literal infringement of claim 2 in US 7,572,920?
- Do the combination claims require fixed-dose products or can combination regimens suffice?
- How do courts typically treat “angII antagonist” language in method-of-use claims like claim 7–9?
- What is the main evidentiary burden for enforcing a process claim like claim 1?
- Which generic label changes most directly reduce risk for method claims covering angII-mediated hypertension?
References
- U.S. Patent 7,572,920 (claim set provided in prompt).
More… ↓
⤷ Start Trial
|
